Comparative Pharmacology
Head-to-head clinical analysis: ASACOL HD versus AZULFIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL HD versus AZULFIDINE.
ASACOL HD vs AZULFIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
Sulfasalazine is a prodrug that is cleaved by gut bacteria to form 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA acts locally in the colon to reduce inflammation by inhibiting prostaglandin synthesis and leukotriene formation, antioxidant effects, and inhibition of cytokine production. Sulfapyridine provides additional immunosuppressive effects.
2 tablets (1600 mg) once daily with or without food.
Oral, 500 mg to 1 g twice daily, initially 500 mg twice daily, increase to 1 g twice daily after 1 week if tolerated; maximum 3 g/day.
None Documented
None Documented
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Sulfapyridine: 10-14 hours; 5-ASA: 0.6-1.4 hours (rapid acetylation). Clinical context: Twice-daily dosing maintains therapeutic sulfapyridine levels.
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Renal: 75% (sulfapyridine metabolites), 15% (5-aminosalicylic acid). Biliary/fecal: 10%.
Category C
Category C
Aminosalicylate
Aminosalicylate